Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality
Molecules · 01.07.2026 · 31 (13) · 2303
DOI: 10.3390/molecules31132303 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 01.07.2026. Verfasst von Jakub Jończyk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, DNA Damage, Synthetic Lethal Mutations, Drug Resistance, Neoplasm. Die Arbeit nennt 130 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jagiellonian University Medical College, Tadeusz and Jan Oświecimski Foundation.
Abstract (Originalsprache)
Triple-negative breast cancer (TNBC), particularly when associated with breast cancer susceptibility gene 1/2 (BRCA1/2) alterations or homologous recombination deficiency (HRD), remains therapeutically challenging because DNA repair vulnerabilities coexist with molecular heterogeneity, resistance, and toxicity constraints. This narrative review synthesizes mechanistic, preclinical, clinical, and translational evidence on DNA damage response (DDR)-targeted and synthetic lethality-based strategies in TNBC. We summarize TNBC biological heterogeneity, current biomarker-guided treatment options, mechanisms of poly(ADP-ribose) polymerase (PARP) inhibition and resistance, and emerging DDR targets, including ataxia telangiectasia and Rad3-related/checkpoint kinase 1 (ATR/CHK1), WEE1, DNA-dependent protein kinase (DNA-PK), RAD51, DNA polymerase theta (POLQ), neddylation-related pathways, and targeted protein degradation. The review highlights that PARP inhibitors and platinum agents provide clinically validated examples of exploiting HRD in selected populations, whereas most next-generation DDR inhibitors remain preclinical, investigational, or in early clinical trials. Resistance mechanisms, including BRCA reversion, homologous recombination restoration, replication fork stabilization, and checkpoint adaptation, limit durable benefit. Safety, target selectivity, overlapping toxicities, and the lack of standardized functional biomarkers further constrain translation. Future progress will require prospective biomarker validation, dynamic HRD assessment, rational scheduling of combinations, and medicinal chemistry approaches that improve therapeutic index rather than a broad application of DDR inhibition across all TNBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland.
- Students Scientific Group of Drug Discovery, Jagiellonian University Medical College, Św. Anny 12, 31-008 Kraków, Poland.
ORCID-Profile: Jakub Jończyk, Anna Czopek, Aleksandra Skok, Agnieszka Zagórska
Förderung
- Jagiellonian University Medical College
- Tadeusz and Jan Oświecimski Foundation
Zitieren
APA
Jończyk, J., Czopek, A., Kvinta, U., Skok, A., & Zagórska, A. (2026). Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality. Molecules, 31(13), 2303. https://doi.org/10.3390/molecules31132303
Vancouver
Jończyk J, Czopek A, Kvinta U, Skok A, Zagórska A. Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality. Molecules. 2026;31(13):2303. doi:10.3390/molecules31132303
BibTeX
@article{Joczyk2026,
author = {Jończyk, Jakub and Czopek, Anna and Kvinta, Ulyana and Skok, Aleksandra and Zagórska, Agnieszka},
title = {Overcoming Resistance in Triple-Negative Breast Cancer: A Translational Perspective on Next-Generation DNA Damage Response Inhibitors and Synthetic Lethality},
journal = {Molecules},
year = {2026},
volume = {31},
number = {13},
pages = {2303},
doi = {10.3390/molecules31132303}
}
EUVIMED